Electrical stimulation treatment for Alzheimer's disease
Clinical Exploratory Research of Medial Prefrontal Cortex Combined With Dorsolateral Prefrontal Cortex Electrical Stimulation in the Treatment of Alzheimer's Disease
This study tests if using electrical stimulation in certain parts of the brain can help improve memory and thinking skills in people with mild to moderate Alzheimer's disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 3 (estimated) |
| Ages | 40 Years to 70 Years |
| Sex | All |
| Sponsor | Xuanwu Hospital, Beijing Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT05971030 on ClinicalTrials.gov |
What this trial studies
This clinical trial explores the use of electrical stimulation targeting the medial prefrontal cortex and dorsolateral prefrontal cortex to treat Alzheimer's disease. The approach involves implanting electrodes in specific brain regions to regulate neural activity, potentially improving cognitive function in patients with mild to moderate Alzheimer's. Participants will be evaluated using cognitive assessment scales to measure the effectiveness of the treatment over time. The study aims to clarify the stimulation targets and their therapeutic effects on memory and cognition.
Who should consider this trial
Good fit: Ideal candidates for this study are males and females aged 40 to 70 diagnosed with mild to moderate Alzheimer's disease.
Not a fit: Patients with significant brain structural abnormalities or other neurological/psychiatric conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for improving cognitive function in Alzheimer's patients.
How similar studies have performed: Previous studies using deep brain stimulation for Alzheimer's have shown mixed results, indicating that while the approach has been tested, its effectiveness remains uncertain.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female aged 40 to 70; 2. eets the diagnostic criteria for mild to moderate AD; 3. A CDR score of 0.5 or 1.0; 4. The MMSE score is between 18 and 28; 5. Regularly taking cholinesterase inhibitors for more than 6 months Exclusion Criteria: 1. Existence of brain structural abnormalities (such as brain tumors, cerebral infarction, and intracranial hematoma); 2. Suffering from other neurological or psychiatric diseases; 3. Accompanying comorbidities that are not suitable for surgical treatment; 4. Individuals with contraindications for MRI or PET testing
Where this trial is running
Beijing
- Xuanwu Hospital — Beijing, China (Recruiting)
Study contacts
- Study coordinator: Yuqing Zhang
- Email: yuqzhang@vip.163.com
- Phone: 83198930
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.